Risk factors for pre-HCT CMV reactivation at multiple levels. Multivariable logistic regression of any (A), ≥150 IU/mL (B), or ≥500 IU/mL (C) viral load CMV in the 90 days before HCT transplant in patients from both eras. ⁺Denotes the lowest pretransplant lymphocyte counts within 7 to 90 days before transplant. ∗Denotes inclusion of unknown or unreported HCT-CI scores. Note that underlying disease categories were collapsed in the pre-HCT reactivation ≥150 and ≥500 IU/mL models due to a lower number of events in each. Specifically, categories include the following: (1) lymphoid malignancies (acute lymphocytic leukemia [ALL], chronic lymphocytic leukemia [CLL], Hodgkin lymphoma [HL], non-Hodgkin lymphoma [NHL], and plasma cell neoplasms); (2) myeloid malignancies (acute myelogenous leukemia [AML], myelodysplastic syndrome [MDS], and other myeloproliferative neoplasms [MPNs]); and (3) Nonmalignant diseases (a variety of diseases such as aplastic anemia [AA] or primary immune deficiencies). 95% CI, 95% confidence interval; PLL, prolymphocytic leukemia.